Clinical trials: Radiation
Breast Cancer
SurgiMend in Two-stage Implant-based Breast Reconstruction in Patients With Pre-Mastectomy Radiotherapy
This is a prospective clinical study comparing two-stage breast reconstruction following mastectomy with and without the use of SurgiMend® PRS fetal bovine collagen matrix in patients with pre-mastectomy radiation therapy.
- Trial name
- NCT01959867
- Testing
- SurgiMend® PRS, No Intervention
- Sponsor
- Integra LifeSciences Corporation
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Bone Metastasis
Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
This purpose of this study is to assess the feasibility of FLASH radiotherapy for the palliative treatment of painful bone metastases.
- Trial name
- FAST-01 (NCT04592887)
- Testing
- FLASH Radiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Varian, a Siemens Healthineers Company
Pleural Neoplasms
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery.
- Trial name
- NCT00087698
- Testing
- pemetrexed, cisplatin
- Where
- 7 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Positioning and Tracking the Prostate During External Beam Radiation
The purpose of this study is to evaluate a non-ionizing electromagnetic method to align the prostate treatment site for radiation therapy and to monitor its position throughout radiation therapy delivery.
- Trial name
- NCT00123838
- Testing
- Calypso® 4D Localization System
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Varian, a Siemens Healthineers Company
Newly Diagnosed and Recurrent Glioblastoma
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
This study will investigate different doses of [177Lu]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of…
- Trial name
- NCT05739942
- Testing
- [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Coronary Artery Disease (CAD), Myocardial Ischemia
A Study of XTR004 Radiotracer in Healthy Volunteers
XTR004 is a 18F-labeled myocardial perfusion positron emission tomography tracer use to measure myocardial perfusion and myocardial blood flow.
- Trial name
- NCT05195879
- Testing
- XTR004
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Mucositis
Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690
Patients expected to receive a continuous course of radiation as single daily fractions of 2.0 Gy treatment with a cumulative radiation dose of 70 Gy. The radiation can be 2DRT, 3DRT,IMRT etc.
- Trial name
- NCT05658016
- Testing
- TK-112690
- Where
- 5 sites in India
- Volunteers
- 24 people
- Sponsor
- Tosk, Inc.
Oral Mucositis, Stomatitis
Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine
The purpose of this study is to compare the incidence of stomatitis when treating with amifostine before radiation treatment.
- Trial name
- NCT01288625
- Testing
- Amifostine
- Sponsor
- Sun Pharmaceutical Industries Limited
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Breast Cancer
Evaluating the Adequacy of Giro-Couch to Support Prone Breast Boost Irradiation Using IMRT Technique With IGRT.
The purpose of this study is to evaluate the Giro-couch, an innovative patient support device for the application of prone RT for treatment of breast cancer.
- Trial name
- IN902 (NCT01016574)
- Testing
- Support Device for Prone radiation therapy (Giro-Couch)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Azimuth Therapy Ltd.
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
This is a multi-center Phase 1 b study designed to expand the patient safety using 99mTc-EC-DG with SPECT/CT imaging and to expand the patient radiation dosimetry and pharmacokinetic database using 99mTc-EC-DG in patients who…
- Trial name
- NCT00864110
- Testing
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Cell>Point LLC
Cancer Pain
35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer
HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability (B-HA injection, Ministry of Health, Registration number L20200708MP07707).
- Trial name
- NCT06209970
- Testing
- HA35
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nakhia Impex LLC
Head and Neck Squamous Cell Carcinoma
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
This biomarker study has been designed to assess the effects of different agents in both tumour tissue and peripheral samples to help inform the best combinations of DDR agents with immuno-oncology (IO) therapies.
- Trial name
- NCT03022409
- Testing
- Ceralasertib, Olaparib
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Osteoporosis
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine…
- Trial name
- NCT00439244
- Testing
- Zoledronic acid, Teriparatide
- Where
- 33 sites in United States, Belgium and 2 more
- Volunteers
- 412 people
- Sponsor
- Novartis
Squamous Cell Carcinoma of the Head and Neck
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
The use of multiple drugs in a single clinical trial or as a therapeutic strategy has become common, particularly in the treatment of cancer.
- Trial name
- NCT02022098
- Testing
- Cisplatin, Radiotherapy, Debio 1143
- Where
- 19 sites in France, Switzerland
- Volunteers
- 144 people
- Sponsor
- Debiopharm International SA
Advanced Solid Tumor Cancer
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection.
- Trial name
- NCT04389281
- Testing
- X-PACT
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Immunolight, LLC